Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to Oncology Articles

Monday 29th November, 2004

 

The results suggest that those receiving more intense therapies are associated with a longer disease free survival than those receiving lower-dose therapies.

 

tellfrnd.gif (30x26 -- 1330 bytes)send to a friend
 
prntfrnd.gif (30x26 -- 1309 bytes)printer friendly version

  Related
 
  AML information  
   

COLUMBUS, Ohio ? New research is helping select which therapies improve the chances of remission in the largest category of people affected by acute myeloid leukemia (AML) ? those whose cancer cells have normal-looking chromosomes.

The findings suggest that people receiving more intense therapies are more likely to enter remission and to remain there longer than those receiving lower-dose therapies.

The study was published online Nov. 8 by the Journal of Clinical Oncology.

The Cancer and Leukemia Group B (CALGB) study was initiated by researchers at the Ohio State University Comprehensive Cancer Center ? Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC-James). It is part of a larger CALGB cytogenetic trial chaired by Clara D. Bloomfield, professor of internal medicine and the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU cancer program.

Unexpectedly, the current study also found that patients who had an enlarged spleen at the time of their initial treatment were less likely to enter remission. AML patients are in remission when leukemic cells are not microscopically detectable among their bone-marrow cells.

?These preliminary findings raise the question of whether additional treatment directed specifically to the spleen might improve remission rates,? says first author Sherif S. Farag, assistant professor of internal medicine and a medical oncologist with the OSU CCC-James. ?At this point, this is just a hypothesis that needs to be tested, but it may be that the spleen is a sanctuary site for leukemic cells and needs separate treatment.?

 

?This study is important because it is the first large study to examine different types of therapy that is restricted to patients with normal chromosomes. Yet, they make up the largest single group of people with AML.?

   

A diagnosis of AML routinely includes studying patients? leukemic cells for chromosome damage, a process known as cytogenetic analysis. The information helps determine the best therapy and a patient?s chance of remission and cure. But 40 percent of AML patients have leukemic cells with normal-looking chromosomes. Without chromosomal abnormalities to guide treatment, several therapies are usually used.

?This study is important because it is the first large study to examine different types of therapy that is restricted to patients with normal chromosomes,? says Krzysztof Mr?ek, an internationally recognized cytogeneticist, research scientist in internal medicine and one of the paper?s coauthors. ?Yet, they make up the largest single group of people with AML.?

The multi-institutional study analyzed data from 490 patients treated for AML through five clinical trials conducted over nearly 20 years. Only adult patients under 60 years of age were included.

Overall, three quarters of the patients achieved complete remission. The average overall survival for the patients was 1.9 years, with 35 percent of patients still alive and disease-free after five years (these patients were considered cured).

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


The researchers first compared the outcomes of patients receiving one of two drug regimens given to bring the disease into remission. The study compared 350 patients receiving the drugs cytarabine plus daunorubicin to 140 patients receiving cytarabine plus increasing doses of both daunorubicin and etoposide.

They found that both treatments induced remission about equally well. But to their surprise, they also found that patients with a normal spleen were four times more likely to enter remission than patients with an enlarged spleen, regardless of therapy.

The researchers then looked at the second phase of treatment, known as intensification therapy, which is intended to keep patients in remission and to enhance the rate of cure.

The study compared four intensification therapies. Of these, the two more-intense therapies each produced longer remission periods and a better chance of cure than did the two less-intense therapies. That is, four cycles of high-dose cytarabine or one cycle of high-dose cytarabine and etoposide followed by stem-cell transplant were more effective than was one cycle of high-dose cytarabine alone.

?There are many different approaches to post-remission therapy, and they include using fewer cycles of high-dose cytarabine or reducing the dose of the drug, but our study suggests these treatments are inferior,? Farag says.

At the same time, the study suggested that using very high doses of cytarabine may also be unnecessary. Using an intermediate dose seems equally effective but has fewer side effects, which can include toxicity to the kidneys and brain.

?This has been suspected, but it hasn?t been carefully studied,? Farag says. ?Again, we need a larger randomized study in the future to verify this, but our data show that we don?t need to push the dose to the maximum to have equal anti-leukemic effect.?

The study also suggested, however, that while two of the four therapies might produce longer remission periods?also known as periods of disease-free survival?no one treatment improved overall survival. The study followed patients for an average 7.4 years. ?More research and some different strategies are still needed to give higher cure rates in these AML patients,? Farag says.

Funding from the National Cancer Institute (NCI) supported this study. The CALGB is a multicenter NCI clinical trials group.

Source

Sherif S. Farag, Amy S. Ruppert, Krzysztof Mr?ek, Robert J. Mayer, Richard M. Stone, Andrew J. Carroll, Bayard L. Powell, Joseph O. Moore, Mark J. Pettenati, Prasad R.K. Koduru, Judith Stamberg, Maria R. Baer, AnneMarie W. Block, James W. Vardiman, Jonathan E. Kolitz, Charles A. Schiffer, Richard A. Larson, and Clara D. Bloomfield (tentatively scheduled for the 1/20/2005 print issue). Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. JCO published November 8, 2004, 10.1200/JCO.2005.06.090

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.